Danaher (NYSE:DHR) Reaches New 1-Year Low Following Analyst Downgrade

Danaher Corporation (NYSE:DHR)’s stock price reached a new 52-week low during trading on Thursday after Morgan Stanley lowered their price target on the stock from $270.00 to $255.00. The company traded as low as $176.60 and last traded at $176.3780, with a volume of 1155776 shares changing hands. The stock had previously closed at $184.04.

Several other research firms also recently commented on DHR. Evercore increased their price objective on shares of Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a report on Tuesday. Wolfe Research dropped their price objective on shares of Danaher from $260.00 to $230.00 and set an “outperform” rating for the company in a report on Wednesday, April 8th. Jefferies Financial Group reissued a “buy” rating and set a $245.00 price objective on shares of Danaher in a report on Tuesday. Argus set a $265.00 price objective on shares of Danaher in a report on Wednesday, January 14th. Finally, Barclays dropped their price objective on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $242.45.

Insiders Place Their Bets

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.80% of the stock is owned by insiders.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight raise to FY EPS range — Danaher beat non‑GAAP EPS estimates ($2.06 vs. consensus) and nudged full‑year adjusted EPS guidance higher, which supports earnings visibility. Earnings Call Highlights
• Positive Sentiment: Bioprocessing momentum and M&A strategy remain drivers — management highlighted strength in bioprocessing and the acquisition pipeline as long‑term growth levers. Q1 Deep Dive
• Neutral Sentiment: Large euro‑denominated senior‑notes offering (~€2.98B net proceeds) — the deal finances operations and transactions but increases liabilities; market reaction depends on how proceeds are used. Notes Offering
• Neutral Sentiment: Masimo acquisition: longer‑term optionality vs. near‑term integration/earnings pressure — analysts note the deal adds strategic upside but may weigh on near‑term returns and capital allocation. Masimo Analysis
• Negative Sentiment: $172.5M shareholder settlement over post‑pandemic demand disclosures — a material cash charge and reputational headwind that increases near‑term litigation/expense risk. Settlement Report
• Negative Sentiment: Revenue miss and Diagnostics softness weighed on the print — core revenue growth was modest and Diagnostics showed weakness (lighter respiratory season at Cepheid), which undercut the EPS beat. Revenue/Segment Notes
• Negative Sentiment: Multiple analyst price‑target cuts (Morgan Stanley, JPMorgan, Wells Fargo, Guggenheim, UBS among others) — downgrades and lower targets increase downside pressure and reduce near‑term analyst support. Morgan Stanley PT Cut

Institutional Investors Weigh In On Danaher

Large investors have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC bought a new stake in Danaher in the third quarter worth about $25,000. Elevated Capital Advisors LLC bought a new stake in Danaher in the fourth quarter worth about $26,000. WFA of San Diego LLC bought a new stake in Danaher in the second quarter worth about $26,000. ANTIPODES PARTNERS Ltd bought a new stake in Danaher in the third quarter worth about $27,000. Finally, Hilton Head Capital Partners LLC bought a new stake in Danaher in the fourth quarter worth about $27,000. 79.05% of the stock is owned by institutional investors.

Danaher Trading Down 2.9%

The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a market cap of $126.49 billion, a P/E ratio of 34.57, a P/E/G ratio of 2.50 and a beta of 0.95. The company’s 50 day simple moving average is $196.45 and its 200-day simple moving average is $214.10.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.88 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, research analysts predict that Danaher Corporation will post 8.4 earnings per share for the current fiscal year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Friday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 annualized dividend and a yield of 0.9%. Danaher’s payout ratio is 30.95%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.